Evidence map›Paper›PMID 30898128›Full record

ArticleMalaria journal2019

Structure-activity relationships in a series of antiplasmodial thieno[2,3-b]pyridines.

Andreas Masch, Abed Nasereddin, Arne Alder, Megan J Bird, Sandra I Schweda, Lutz Preu, Christian Doerig, Ron Dzikowski, Tim W Gilberger, Conrad Kunick

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. β-Ketoamides in Thieno[2,3-Molecules (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Design, synthesis and evaluation of amino-3,5-dicyanopyridines and thieno[2,3-b]pyridines as ligands of adenosine AMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. 4-Arylthieno[2,3-Molecules (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Andreas MaschInstitut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Beethovenstraße 55, 38106, Braunschweig, Germany.
Abed NasereddinDepartment of Microbiology and Molecular Genetics, IMRIC, The Kuvin Center for the Study of Infectious and Tropical Diseases, The Hebrew University-Hadassah Medical School, 91120, Jerusalem, Israel.
Arne AlderCentre for Structural Systems Biology, Deutsches Elektronen-Synchrotron, Notkestraße 85, 22607, Hamburg, Germany.
Megan J BirdBiomedicine Discovery Institute, Infection & Immunity Program, Department of Microbiology, Monash University, Clayton, VIC, 3800, Australia.
Sandra I SchwedaInstitut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Beethovenstraße 55, 38106, Braunschweig, Germany.
Lutz PreuInstitut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Beethovenstraße 55, 38106, Braunschweig, Germany.
Christian DoerigBiomedicine Discovery Institute, Infection & Immunity Program, Department of Microbiology, Monash University, Clayton, VIC, 3800, Australia.
Ron DzikowskiDepartment of Microbiology and Molecular Genetics, IMRIC, The Kuvin Center for the Study of Infectious and Tropical Diseases, The Hebrew University-Hadassah Medical School, 91120, Jerusalem, Israel.
Tim W GilbergerCentre for Structural Systems Biology, Deutsches Elektronen-Synchrotron, Notkestraße 85, 22607, Hamburg, Germany.
Conrad KunickInstitut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig, Beethovenstraße 55, 38106, Braunschweig, Germany. c.kunick@tu-bs.de.ORCID http://orcid.org/0000-0001-7041-5322
Technische Universität Braunschweig · DEAustralian Regenerative Medicine Institute · AUCentre for Structural Systems Biology · DEHebrew University of Jerusalem · IL

Funding

Bundesministerium für Bildung und Forschung 13GW0024Bundesministerium für Bildung und Forschung BMBF BioDisc 7European Cooperation in Science and Technology CM1307
6 · The paper itself

Abstract

backgroundMalaria is one of the most prevalent tropical infectious diseases. Since recently cases of artemisinin resistance were reported, novel anti-malarial drugs are required which differ from artemisinins in structure and biological target. The plasmodial glycogen synthase kinase-3 (PfGSK-3) was suggested as a new anti-malarial drug target. 4-Phenylthieno[2,3-b]pyridines were previously identified as selective PfGSK-3 inhibitors with antiplasmodial activity. The present study aims at identifying a molecular position on this scaffold for the attachment of side chains in order to improve solubility and antiplasmodial activity. Furthermore, the role of axial chirality in the compound class for antiplasmodial activity and PfGSK-3 inhibition was investigated.

methods4-Phenylthieno[2,3-b]pyridines with substituents in 4-position of the phenyl ring were docked into the ATP binding site of PfGSK-3. The compounds were synthesized employing a Thorpe reaction as final step. The enantiomers of one congener were separated by chiral HPLC. All derivatives were tested for inhibition of asexual erythrocytic stages of transgenic NF54-luc Plasmodium falciparum. Selected compounds with promising antiplasmodial activity were further evaluated for inhibition of HEK293 cells as well as inhibition of isolated PfGSK-3 and HsGSK-3. The kinetic aqueous solubility was assessed by laser nephelometry.

resultsThe para position at the 4-phenyl ring of the title compounds was identified as a suitable point for the attachment of side chains. While alkoxy substituents in this position led to decreased antiplasmodial activity, alkylamino groups retained antiparasitic potency. The most promising of these congeners (4h) was investigated in detail. This compound is a selective PfGSK-3 inhibitor (versus the human GSK-3 orthologue), and exhibits improved antiplasmodial activity in vitro as well as better solubility in aqueous media than its unsubstituted parent structure. The derivative 4b was separated into the atropisomers, and it was shown that the (+)-enantiomer acts as eutomer.

conclusionsThe attachment of alkylamino side chains leads to the improvement of antiplasmodial activity and aqueous solubility of selective PfGSK-inhibitors belonging to the class of 4-phenylthieno[2,3-b]pyridines. These molecules show axial chirality, a feature of high impact for biological activity. The findings can be exploited for the development of improved selective PfGSK-3 inhibitors.

Indexed as

AntimalarialsGlycogen Synthase Kinase 3HEK293 CellsHumansMalaria, FalciparumPlasmodium falciparumProtozoan ProteinsPyridinesStructure-Activity RelationshipAntimalarialsGlycogen Synthase Kinase 3Protozoan ProteinsPyridinesAnti-malaria drugsAtropisomersAxial chiralityDrug discoveryMalariaPfGSK-3Plasmodium falciparumProtein kinaseThienopyridinesThorpe cyclization

Identifiers

PMID30898128
PMCPMC6429710
OpenAlexW2943216147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.